#1GINKGO BIOWORKS Grow with Ginkgo 2021 Update & Business Review March 28, 2022 T#2Disclaimer Forward-Looking Statements This presentation, the conference call and webcast may contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, current expectations, operations and anticipated results of operations, both business and financial, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the effect of the business combination between Ginkgo Bioworks Holdings, Inc. ("Ginkgo") and Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's business relationships, performance, and business generally, (ii) risks that the business combination disrupts current plans of Ginkgo and potential difficulties in Ginkgo's employee retention, (iii) the outcome of any legal proceedings that may be instituted against Ginkgo related to its business combination with Soaring Eagle, (iv) volatility in the price of Ginkgo's securities now that it is a public company due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates, variations in performance across competitors, changes in laws and regulations affecting Ginkgo's business, changes in the combined capital structure and expectations associated with increases in the number of shares available for sale, (v) the ability to implement business plans, forecasts, and other expectations after the completion of the business combination, and ability to identify and realize additional opportunities, (vi) the risk of downturns in demand for products using synthetic biology, (vii) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19 testing business, and (viii) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on November 15, 2021, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Any forward-looking statement made by us in this presentation, the conference call during which this presentation is reviewed and any discussions that follow speaks only as of the date on which it is made. You are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. Industry and Market Data In this presentation, Ginkgo relies on and refers to certain information and statistics regarding the markets and industries in which Ginkgo competes. Such information and statistics are based on Ginkgo management's estimates and/or obtained from third-party sources, including reports by market research firms and company filings. While Ginkgo believes such third-party information is reliable, there can be no assurance as to the accuracy or completeness of the indicated information, and Ginkgo has not independently verified the accuracy or completeness of the information provided by the third-party sources. Trademarks This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners, and Ginkgo's use thereof does not imply an affiliation with, or endorsement by, the owners of such trademarks, service marks, trade names and copyrights. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, Oor symbols, but Ginkgo will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights. Non-GAAP Financial Measures Certain of the financial measures included in this presentation, including Adjusted EBITDA, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this presentation, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures.#3Agenda Introduction Jason Kelly, Co-Founder and CEO 2021 Full Year Financial Update Mark Dmytruk, CFO Strategic Positioning Jason Kelly, Co-Founder and CEO Q&A Session Moderated by Anna Marie Wagner, SVP Corporate Development Property of Ginkgo Bioworks - 3 2021 UPDATE & BUSINESS REVIEW#4Capital markets have been tough on growth biotech, but Ginkgo is in a stronger position than at any time in our history Daily Strain Tests Active Programs 49 5 11 14 13 6 2020 10,000,000 1,000,000 100,000 10,000 1,000 100 Diversified Business with Demonstrated Technical Success 10 Jan-151 Jan-16 71 5 Jan-17 18 21 17 10 2021 Government Jan-18 Pharma & Biotech Food & Agriculture Driving adoption of new technologies that yield step-change increases Industrial & Environmental Consumer & Technology Jan-19 Strain tests scaling 3x+ / year Jan-20 Jan-21 Jan-22 Multiple Recent Program Successes Ginkgo has more than doubled the number of products in scale production by our customers so far this year in diverse fields... Product Ginkgo organlar? Ginkgo proces Approx Year Started Year Completed Custona Primary End Market Organis Product Type Mig Scale H Downstream Sconomic Peach ✓ 2014 2019 Je ROBENTET Consumer Even 1500 Coconut [Confidential Royalty To ✓ 2010 2019 ROMAILT Consumer Boecies 3 ✓ Roy 2018 2018 (Content Chanical Rot Royal VCE Gregobam ✓ ✓ 2020 2021 Caldevron Pharma Myoglobin ✓ Ryany 2011 2021 Food Fungor Species G Equity CBG ✓ 2013 Launched first "Cell Development Kits" for protein production 2021 CRONOS Consumer Fungol Species cies 3 Species 4) Pict Sal Melecule Most being produced in tank at the 25,000-50,000 scale some pharme products produced at lower scals frundets to 1000L) NA Foo for service Small Molecule Confidential Miestone ✓ 2000 2021 Condema Pharma Bota Soacias CBGV ✓ ✓ 2010 2021 CRONOS Consumer Fal 500ps 5 Mestone Excerpt from Q3 2021 Earnings Deck O Integrated, Horizontal Platform Technology K 4x Y-O-Y Revenue Growth $77 $17 $59 2020 Strong Financial Health $314 $201 $113 2021 Biosecurity ($M) Foundry ($M) $1.5+ billion in cash yields runway ample 640+ World class team members Organizations served by 4,000+ Concentric, Ginkgo's biosecurity business (as of 3/20/2022) 313,000+ Square feet of lab space Property of Ginkgo Bioworks - 4 2021 UPDATE & BUSINESS REVIEW#5Ginkgo operates as a cell programming platform; scale effects are critical for both profitable economics on programs and for diversification across markets Ginkgo Foundry Input Customer Specs Recursive Learning SOFTWARE HARDWARE ORGANISMS ... Design, Write, & Debug DNA Code ACTGGATA CCTGAGAT AUTOMATION GENETIC CODE BIOLOGICAL TOOLS Continuous Improvement Output Cell Program Ginkgo Codebase Property of Ginkgo Bioworks - 5 2021 UPDATE & BUSINESS REVIEW#6Agenda Introduction Jason Kelly, Co-Founder and CEO 2021 Full Year Financial Update Mark Dmytruk, CFO Strategic Positioning Jason Kelly, Co-Founder and CEO Q&A Session Moderated by Anna Marie Wagner, SVP Corporate Development Property of Ginkgo Bioworks - 6 2021 UPDATE & BUSINESS REVIEW#7Total Ginkgo Revenue (Unaudited) $32M $16M $16M Q4 2020 363% $148M $114M $34M Q4 2021 $77M $17M $59M FY 2020 309% $314M $201 M $113M FY 2021 Biosecurity Foundry Property of Ginkgo Bioworks - 7 2021 UPDATE & BUSINESS REVIEW#8Cell Programming Highlights (Unaudited) 3 22 Q4 2020 233% Q4 2020 36% New Programs 10 Q4 2021 30 18 Total Active Customers Q4 2021 FY 2020 72% 22 50% FY 2020 31 FY 2021 33 FY 2021 44 Q4 2020 108% Total Active Programs 36% $16 $4 $13 Q4 2020 Related Party 60 Q4 2021 Third-party 49 Foundry Revenue ($M) $34 $24 $10 Q4 2021 45% FY 2020 $59 $17 $43 91% FY 2020 71 FY 2021 $113 $66 $47 FY 2021 Property of Ginkgo Bioworks - 8 2021 UPDATE & BUSINESS REVIEW#9Biosecurity Highlights (Unaudited) $22 Q1 2021 -10% Q1 2021 Biosecurity Revenue ($M) $22 Q2 2021 22% $43 Biosecurity Gross Margin Q2 2021 Q3 2021 48% Q3 2021 $114 Q4 2021 42% Q4 2021 Concentric's pathogen monitoring network has conducted testing across most of the U.S.(1) Demonstrated ability to deliver testing in diverse jurisdictions States in which Concentric has delivered testing services Airport testing locations 7,200,000+ Samples to date 4,000+ Organizations supported to date 4 Key US airports (1) Map shading reflects all states in which Concentric has delivered testing since launching in 2020, not all states currently have active testing. programs. Breadth is important given diverse set of state operating models. Data updated 03/27/22 Expanding our reach through partnerships with Eurofins' Clinical Enterprise and acquisition of Project Beacon COVID-19 Air travel SARS-CoV-2 genomic surveillance program in partnership with XpresCheck and CDC yielded first U.S. detections of Omicron sublineages BA.2 and BA.3 Property of Ginkgo Bioworks - 9 2021 UPDATE & BUSINESS REVIEW#102021 Financial Summary (Unaudited) In millions of USD except new programs and % YoY New programs launched Revenue: Foundry Biosecurity Total revenue Biosecurity cost of sales Research and development (excl. SBC) General and administrative (excl. SBC) Total operating expenses (excl. SBC) Stock-based compensation (1) Loss from operations Net loss Adjusted EBITDA Capital expenditures Three Months Ended December 31, 2021 10 34 114 148 67 55 39 160 1,673 (1,685) (1,605) 1 5 (1) For the year ended December 31, 2021, amount includes $5.0M of employer payroll taxes related to stock-based compensation 2020 3 16 16 32 14 61 13 88 。 O (56) (46) (51) 19 % YoY 233% 108% NM 363% 381% (11%) 205% 83% NM NM NM NM (74%) Year Ended December 31, 2021 31 113 201 314 130 219 106 455 1,688 (1,828) (1,837) (106) 57 2020 18 59 17 77 16 160 38 213 O (137) (127) (121) 58 % YoY 72% 91% NM 309% 731% 37% 179% 113% NM NM NM 13% (2%) 10 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#112022 Full Year Outlook In millions of USD except new programs and % YoY New Programs GAAP Revenue Foundry Biosecurity Total Revenue Historical FY2020 FY2021 (20-21) 18 $59 $17 $77 31 $113 $201 $314 72% 91% NM 309% Outlook FY2022 60 $165 - $180 $160+ $325 - $340+ Property of Ginkgo Bioworks - 11 2021 UPDATE & BUSINESS REVIEW#12Agenda Introduction Jason Kelly, Co-Founder and CEO 2021 Full Year Financial Update Mark Dmytruk, CFO Strategic Positioning Jason Kelly, Co-Founder and CEO Q&A Session Moderated by Anna Marie Wagner, SVP Corporate Development 12 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#13We believe... 1 Ouch. And yet... Ginkgo is in a stronger position now than at any time in our past The market has cooled dramatically for biotech and growth stocks, however Ginkgo has exceeded its targets across almost every dimension. 2 It's hard to achieve scale as a platform cell programming company If it wasn't hard, there would be a lot more success stories. We may be able to program them, but make no mistake: cells are not computers. Everything we are building, from the technology to the business model, poses obstacles to reaching large scale. But our relative scale and cash balance position us well to achieve success. 3 If it's so hard, why try? Because we must. The status quo needs to change, and we have the scale and time to try to pull it off. If we do, it will be both valuable and impactful. 13 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#14We believe... 1 Ouch. And yet... Ginkgo is in a stronger position now than at any time in our past The market has cooled dramatically for biotech and growth stocks, however Ginkgo has exceeded its targets across almost every dimension. 2 It's hard to achieve scale as a platform cell programming company 3 If it's so hard, why try? 14 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#15The current market environment will provide both challenges and opportunities to Ginkgo and our shareholders BIOTECH STAT+ 'Nowhere to hide': As biotech stocks plummet, an industry is being reshaped by the fallout By Adam Feuerstein, Damian Garde and Matthew Herper Jan. 28, 2022 Reprints "So, if the company is better positioned today than it was a year ago, why is the stock price so much lower than it was a year ago? As the famed investor Benjamin Graham said, “In the short term, the stock market is a voting machine; in the long term, it's a weighing machine." Clearly there was a lot of voting going on in the boom year of '99 – and much less weighing. We're a company that wants to be weighed, and over time, we will be - over the long term, all companies are. In the meantime, we have our heads down working to build a heavier and heavier company." Shareholder Letter from Jeff Bezos 2000 Amazon.com Annual Report 15 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#16Ginkgo is in a stronger position now vs. any time in our history Strong Financial Health Strong performance: exceeded all of our public KPIs in 2021 Long runway: ended the year with over $1.5 billion in cash, providing meaningful multi-year runway as we drive towards profitability Diversified Customer Base Healthy mix of programs across all axes Individual end-markets can come in and out of favor (e.g., biofuels); diversification insulates us from these dynamics New Business Running at Scale in Biosecurity New Programs Strategic Position Strengthened 30 7 23 Outlook Program Segmentation 31 31 Actuals Mature 35% Customer Size Mid-stage 25% Foundry Revenue $100+ $100+ Outlook Early-stage 40% $113 $113 Actuals Biosecurity Revenue $201 Third Party 46% $110+ $60 $50 Outlook Partnership Type Structured Partnership 23% Platform Venture 31% $201 Actuals Industry Govt. 7% Pharma & Biotech 25% Current market environment will benefit well-capitalized industry leaders Opportunity to continue long-term scaling plans (while narrow competitors may need to focus on nearer-term opportunities), including platform investments and M&A Scaled business from $17 million to $201 million of profitable revenue in one year Established credibility as a leading provider of K-12 testing and are now working with the public sector to help define what a stable biosecurity infrastructure needs to look like Food & Ag. 30% Cons. & Tech 14% Preliminary Outlook Revised Outlook Actuals Ind. & Environ. 24% 16 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#17We believe... 1 Ouch. And yet... Ginkgo is in a stronger position now than at any time in our past 2 It's hard to achieve scale as a platform cell programming company If it wasn't hard, there would be a lot more success stories. We may be able to program them, but make no mistake: cells are not computers. Everything we are building, from the technology to the business model, poses obstacles to reaching large scale. But our relative scale and cash balance position us well to achieve success. 3 If it's so hard, why try? 17 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#18Being a sub-scale cell programming platform will be difficult in this new market environment "Online selling (relative to traditional retailing) is a scale business characterized by high fixed costs and relatively low variable costs. This makes it difficult to be a medium-sized e-commerce company. With a long enough financing runway, Pets.com and living.com may have been able to acquire enough customers to achieve the needed scale. But when the capital markets closed the door on financing Internet companies, these companies simply had no choice but to close their doors." Shareholder Letter from Jeff Bezos 2000 Amazon.com Annual Report Ginkgo benefits from its current relative scale and runway 18 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#19Biology, unlike computers, isn't predictable "This is a unique moment in our relationship with biology. The COVID-19 pandemic has shown how a tiny bit of RNA code can upend our entire world and how mRNA vaccines can give us hope that we can bring the pandemic under control. It is also a reminder that while biology programmable like a computer, it is not predictable like a computer." is Ginkgo Founder's Letter (in S-4 Filing), May 2021 19 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#20Maintaining exponentially improving technology like Knight's Law is hard, complex work... Daily Strain Tests Daily Strain Tests: MEASURING THE OUTPUT OF THE PLATFORM 10,000,000 1,000,000 100,000 10,000 1,000 100 10 Strain tests scaling 3x+/year Jan-15 COVID impact Jan-16 Jan-17 Jan-18 Jan-19 Jan-20 Jan-21 Jan-22 Key Drivers & Challenges New biological tools: New techniques can create "step change" leaps for certain types of experiments Challenge then becomes how to more broadly deploy these techniques Not all Foundry technologies scale at the same rate GenomeWeb fgen Ginkgo Bioworks to Acquire Swiss Bioengineering Firm FGen NEW YORK - Ginkgo Bioworks said on Monday that it has signed a definitive agreement to acquire FGen, a Swiss contract research organization... Automation: Focused on increasing automation across workflows as they mature Difficult to balance scalability and flexibility Miniaturization: Miniaturization not only drives down reagent usage but these techniques are often higher throughput (e.g. pipette-less liquid handling) Requires constant investment in new technologies (exponential scale tends to "break" current supply chains, often quickly - e.g. pipette tips, plates, etc.) 20 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#21...but still easier than trying to scale the status quo of manual lab work exponentially! Cost / Strain Test (Rolling 3 Month Average) Cost per Strain Tests: MEASURING THE EFFICIENCY OF THE PLATFORM $10,000 $1,000 $100 $10 $1 Jan-15 Jan-16 Unit costs / strain test falling approx. 50% / year Jan-17 Jan-18 Jan-19 COVID impact Jan-20 Jan-21 We believe "by hand" lab techniques get "stuck" and have minimal (if any) improvements over time and with scale It took us about 8 years from founding to reach cost parity with "by hand" lab work, but now that we have, our cost advantage will become more and more significant 21 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#22As Knight's Law matures we will need increased industry coordination to maintain exponential improvements over time Year of Production Technology Node (c) Additional Design Technology Requirements 2003 2004 2005 2006 2007 2008 2009 2012 2015 2018 hp90 hp65 90 65 DRAM 2 Pitch (nm) MPU/ASIC 2 Pitch (nm) MPU Printed Gate Length (nm) MPU Physical Gate Length (nm) SOC new design cycle (months) SOC logic Mtx per designer-year (10-person team) SOC dynamic power reduction beyond scaling (X) SOC standby power reduction beyond scaling (X) %Test covered by BIST Mtx-Million transistors 100 107 65 45 12 1.9 0 0.37 20 90 53 7 12 251 14 20 37 0.1 80 80 45 32 12 3.3 0.1 2.4 25 70 70 40 28 12 4.3 0.2 3.4 30 65 35 25 5.4 0.2 5.1 35 57 57 32 22 20 12 11 7.4 10.6 0.2 6.4 40 50 50 28 Manufacturable solutions exist, and are being optimized Manufacturable solutions are known 0.2 8.73 45 35 35 20 14 24.6 6 18.8 60 Interim solutions are known Manufacturable solutions are NOT known Source: 2003 ITRS, Tables A, B, and 19, 1, 7, 124. 25 25 15 10 10 73.4 113 4.7 18 18 10 ~~~ 75 7 T 8.1 44.4 232 90 Driver SOC SOC SOC SOC MPU, SOC The semiconductor industry required the development of many technologies in parallel to achieve industry scaling goals We expect biotechnology to have a similar dynamic 107 106 105 104 103 10² 101 10⁰ 1970 40 Years of Microprocessor Trend Data 1980 Moore's Law 444 1990 Year प्रक 2000 2010 Transistors (thousands) Single-Thread Performance (SpecINT x 103 Frequency (MHz) Typical Power (Watts) Number of Logical Cores 2020 Source: 2021 ITRS 22 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#23If Ginkgo is successful, it will necessitate an increase in scale of key tools and/or adjacent capacity Reagents/ Consumables (e.g. pipette tips) Usi DESIGN BUILD Long R&D cycles will help adjacent sectors meet scaling needs, but we may find we need to help close certain gaps E.g. we're watching the animal-free protein space, which has had significant recent success and is currently facing a gap in pilot scale manufacturing TEST Microorganism- based Exhibit 7-Taste, Texture, and Price Parity Depends on Improvements in Key Steps in the Value Chain Source FERMENT 1 Increase in metabolic efficiency Production and sourcing Growth 2 Adoption of low- cost feedstocks Harvest Extraction. Feedstocks (e.g. sugar or novel feedstocks) 3 Optimization of harvesting and protein extraction processes¹ Fermentation Capacity (e.g. tanks and/or novel methods) Processing Formulation > Texturizing 4 Reduction in the cost and complexity of additives Source: BCG, "Food for Thought - The Protein Transformation", March 2021 23 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#24Codebase reuse is better for the whole industry, enabling more product successes and helping spur market growth, but requires changing the status quo IP regime in biotech GINKGO BIOWORKS Grow with Ginkgo: You're a Cell Developer We've developed a cell programming platform to make biology easier to engineer. And we made it for you! Join this virtual event to learn how you can use our platform to grow the future! Thursday, Nov. 11-10:00am - 12:00pm ET Register CDKS-launched in Q4 - help demonstrate value of IP sharing across the industry, shortening development timelines and increasing probability of success First two CDKs are focused on protein production We believe they currently represent the state of the art in protein production Pichia Pastoris Filamentous Fungi Ginkgo Pichia Promoters vs Best In Class Ginkgo's synthetic promoters were 5-20X stronger than best-in-class Fold improvement over BIC promoter 20 15 10 5 Best In Class Ginkgo Synthetic Ginkgo Synthetic Ginkgo Synthetic Promoter 2 Promoter 3 Promoter 1 DUTCH DNA a heartbeat ahead Developing additional, diverse CDKs is a top R&D priority 24 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#25Biotechnology products take significant time to get to market; both scale and diversity are needed to achieve predictable cash flows Downstream "Present Value" Will Move with Broader Markets Equity: Drop in growth & biotech valuations drives lower marks for existing equity positions Effect is felt immediately as equity is a present value measurement (of expected future value) Cash Milestones & Royalties: Milestones and royalties are only paid upon program success / commercialization and are thus delayed Higher discount rates similarly drive a lower NPV for these future expected payments Ended 2021 with over $1.5 billion in cash Provides meaningful multi-year runway as we drive towards profitability Risk Tunable Balance of Risk Sharing We can adjust the balance between upfront fees and downstream value based on the customer and Ginkgo's position No / Low Upfront Fees High Downstream Value High Upfront Fees No / Low Downstream Value (e.g. a traditional CRO model) When profitable / well capitalized, can lean into our differentiated p(success) Can shift focus towards need to preserve cash cost-covering upfront fees if Return if successful 25 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#26Platforms are dependent on customers bringing products to market Ginkgo has more than doubled the number of products in scale production by our customers so far this year in diverse fields... Product Ginkgo organism? Ginkgo process? Approx. Year Started Year Completed Customer Primary End Market Organism Product Type Mfg Scale (L) Downstream Economics Peach ✓ ✓ 2014 2019 03% ROBERTET Consumer Fungal (Species 1) Small Molecule Coconut [Confidential] Royalty/Toll ✓ 2016 2019 ROBERTET Consumer Fungal (Species 2) Small Molecule ✓ Royalty/Toll ✓ 2016 2018 (mig began in 2020) [Confidential] Chemicals Bacterial (Species 3) Small Molecule VCE Royalty/Toll ✓ ✓ 2020 2021 Caldevron Pharma Bacterial (Species 4) Protein Myoglobin Royalty ✓ ✓ 2018 2021 moti Food Fungal (Species 5) Protein Equity CBG Note: "Ginkgo organism" refers to a strain engineered by Ginkgo, whereas "Ginkgo process" refers to a manufacturing process developed by Ginkgo ✓ ✓ 2018 2021 CRONOS GROUP Consumer Fungal (Species 6) Small Molecule [Confidential] Milestone ✓ Most being produced in tanks at the 25,000 - 50,000L scale; some pharma products produced at lower scale (hundreds to 1.000L) 2020 2021 [Confidential] Pharma Bacterial (Species 4) Nucleic Acid N/A Fee for service CBGV ✓ ✓ 2018 2021 CRONOS GROUP Consumer Fungal (Species 6) Small Molecule Pilot Scale Milestone Property of Ginkgo Bioworks - 28 Q3 UPDATE & BUSINESS REVIEW Excerpt from Q3 2021 Earnings Call We must continue to drive a diverse set of programs to completion... ...and then rely on our customers to successfully bring those products to market 26 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#27Overexposure to a narrow market can mean that if that market stumbles the platform can fail. We plan to remain horizontal. Cumulative Programs Archetype Late-Stage Examples Consumer & Technology 14 2020 ROBERTET 18 CRONOS GROUP 2021 Peach and coconut flavors Industrials & Environment CBG and CBGV successfully produced 18 • Wide variation in program types: o New product innovation (higher risk / higher value share) and drop-in-replacements (lower risk / lower value share) o Commodity segments (lower value share) vs. specialty ingredients (higher value share) • Historically focused on cost and sustainability, increasingly focused on new functionality 2020 26 Confidential 2021 Small molecule chemical Food & Agriculture 23 2020 31 2021 • Many projects involve a deeper "discovery" element (higher risk, higher value share) . Moderate time to market, depending on regulatory framework Hemami GRAS motif Certification JOYN Early Nitrogen BIO Fixation field trials Pharma & Biotech 13 2020 aldevron® ● Majority of programs are geared towards creating new products and have extensive regulatory requirements / oversight • High risk (i.e. clinical failure) offset by high margins (and higher royalty rates) Confidential 24 synlogic 2021 >10x improvement Nucleic acid vaccine (in trials) IND-enabling studies 27 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#28Our biosecurity business will need to evolve as we move from pandemic response to pandemic prevention HEALTH The Atlantic America Is Zooming Through the Pandemic Panic-Neglect Cycle All epidemics trigger the same Sisyphean cycle of panic and neglect. Even so, that cycle isn't meant to spin this quickly. By Ed Yong MARCH 17, 2022 Many state contracts expire July 1, 2022. Still to be seen what, if any, long-term measures will be put in place. We will remain conservative in our biosecurity guidance until it is clear what is being built and how Ginkgo will participate in the new biosecurity ecosystem. The New York Times AC.D.C. airport surveillance program found the earliest known U.S. cases of Omicron subvariants. By Emily Anthes March 24, 2022 NET An airport-based coronavirus surveillance program in the United States for travelers arriving from abroad detected the first known U.S. case of the highly contagious Omicron subvariant BA.2 in December, according to a new study. 28 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#29We believe... 1 Ouch. And yet... Ginkgo is in a stronger position now than at any time in our past 2 It's hard to achieve scale as a platform cell programming company 3 If it's so hard, why try? Because we must. The status quo needs to change, and we have the scale and time to try to pull it off. If we do, it will be both valuable and impactful. 29 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#30Breakthrough technology companies often have longer times to profitability. Low interest rate environment has led to a blossoming of these companies in the US over the last 15 years. The list of successful car company startups is short. As of 2016, the number of American car companies that haven't gone bankrupt is a grand total of two: Ford and Tesla. Starting a car company is idiotic and an electric car company is idiocy squared. Elon Musk, Tesla "Master Plan Part Deux", July 2016 WSJ Wall Street Journal IPOS Had a Record 2021. Now They Are Selling Off Like Crazy. Threats of higher rates are driving down prices of high-growth stocks; two- thirds of 2021 IPOs now sit below their offer prices. Dec 29, 2021 WSJ Wall Street Journal With Rate Increases Looming, Investors Dump Shares of Money-Losing Companies As the Federal Reserve moves closer to raising interest rates, ... The performance of riskier growth stocks, which aim to deliver sharp... Jan 18, 2022 Robinhood 66 "" ◆WSJ NEWS EXCLUSIVE Nuclear-Fusion Startup Lands $1.8 Billion as Investors Chase Star Power No one has been able to generate net energy by combining atoms, yet Commonwealth Fusion Systems has attracted Bill Gates and George Soros Helion secures $2.2B to commercialize fusion energy Haje Jan Kamps @Haje / 10:01 AM EDT - November 5, 2021 Creating a rocket company has to be one of the dumbest and hardest ways to "make money". If it was about money, I'd just do another Internet company." Elon Musk, Twitter, March 2018 30 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#31It's easy to underestimate biology's potential. These are hard problems worth solving. of the world's physical inputs 60% could be made using biological means 45% 30% of the world's disease burden could be addressed of private-sector R&D spent in biology-related industries 99 Exhibit E4 In ten to 20 years, a visible pipeline of biological applications could create approximately $2 trillion to $4 trillion of direct annual economic impact. Partial estimate of potential and direct annual impact by time horizon¹ $ trillion Time horizon Source: McKinsey Global Institute, The Bio Revolution, May 2021 0.6-1.5 Shorter (2020-30) 1.8-3.6 Medium (2030-40) 3.0-5.1 Longer (2040-50) Impact not assessed² High estimate Low estimate Read More 31 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#32Several discrete catalysts that could change the game. Strong demand, across both startups and large enterprise customers, likely to lead to meaningful new partnerships (though timing can be lumpy) Deep M&A pipeline across both tuck-in technologies and more transformative opportunities Demonstrated ability to scale rapidly and pivot as emerging opportunities arise, e.g. biosecurity It's shaping up to be an exciting 2022! 32 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#33WINT Let's build the world we want to see#34Agenda Introduction Jason Kelly, Co-Founder and CEO 2021 Full Year Financial Update Mark Dmytruk, CFO Strategic Positioning Jason Kelly, Co-Founder and CEO Q&A Session Moderated by Anna Marie Wagner, SVP Corporate Development Property of Ginkgo Bioworks - 34 2021 UPDATE & BUSINESS REVIEW#35APPENDIX 000#36Cell Program Counts New Programs Current Active Programs Cumulative Programs Three Months Ended December 31, 2021 10 60 105 2020 3 44 74 Year Ended December 31, 2021 31 71 105 2020 18 49 74 New Programs: New Programs represent the number of unique programs commenced within the reporting period. As new programs have multi-year durations, we view this metric as an indication of future Foundry revenue growth. Current Active Programs: Current Active Programs represent the number of unique programs for which we performed R&D services in the reporting period. We view this metric as an indication of current period and future Foundry revenue. Cumulative Programs: Cumulative Programs represent the cumulative number of unique programs Ginkgo has commenced. We view this metric as an indication of our competitive advantage and as a leading indicator of the mid- to long-term potential economic value derived from downstream value share arrangements. The cumulative number of programs also contributes to Codebase, which accumulates with each additional program we conduct over time and drives better experimental direction and improves the odds of technical success in current and future programs. 36 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#37Cell Program Counts - Quarterly New Programs Current Active Programs Cumulative Programs Mar 31, 2021 4 44 78 Jun 30, 2021 7 46 Three Months Ended 85 Sep 30, 2021 10 54 95 Dec 31, 2021 10 60 105 New Programs: New Programs represent the number of unique programs commenced within the reporting period. As new programs have multi-year durations, we view this metric as an indication of future Foundry revenue growth. Current Active Programs: Current Active Programs represent the number of unique programs for which we performed R&D services in the reporting period. We view this metric as an indication of current period and future Foundry revenue. Cumulative Programs: Cumulative Programs represent the cumulative number of unique programs Ginkgo has commenced. We view this metric as an indication of our competitive advantage and as a leading indicator of the mid- to long-term potential economic value derived from downstream value share arrangements. The cumulative number of programs also contributes to Codebase, which accumulates with each additional program we conduct over time and drives better experimental direction and improves the odds of technical success in current and future programs. 37 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#38Adjusted EBITDA Reconciliation (Unaudited) Three Months Ended December 31, 2021 In millions of USD Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders Interest income Interest expense Income tax (benefit) provision Depreciation and amortization EBITDA Stock-based compensation (¹) Loss on equity method investments (2) Loss (gain) on investments (3) Change in fair value of warrant liabilities Gain on settlement of partnership agreement Other (4) Adjusted EBITDA $ (1,600.7) (0.5) 0.6 (0.7) 8.0 $ (1,593.3) 1,672.8 4.1 14.6 (77.1) (22.8) 2.3 $ 0.6 2020 $ (46.9) (0.1) 0.6 0.0 4.0 $ (42.5) 0.1 (1.2) (1.2) 0.0 (0.7) (5.3) $ (50.8) Year Ended December 31, 2021 $ (1,830.0) (0.8) 2.4 (1.5) 29.1 $ (1,800.9) 1,687.6 74.4 11.5 (58.6) (23.8) 3.7 $ (106.0) 2020 $ (126.6) (2.6) 2.4 1.9 13.9 $ (111.1) 0.5 0.3 3.7 0.0 (8.3) (6.6) $ (121.4) (1) For the three months ended and the year ended December 31, 2021, includes $5 0 million in employer payroll taxes related to stock-based compensation (2) For the three months ended December 31, 2021 and 2020, represents losses on equity method investments under the hypothetical liquidation at book value ("HLBV") method of $4 7 million and $1 8 million, respectively, net of losses attributable to non-controlling interests For the years ended December 31, 2021 and 2020, represents losses on equity method investments under the HLBV method of $77 3 million and $0 4 million, respectively, net of losses attributable to non-controlling interests (3) Includes loss on the change in fair value of our common stock investments in Synlogic and Cronos and warrants to purchase Synlogic common stock, which are all carried at fair value (4) For the three months ended and the year ended December 31, 2021, includes mark-to-market adjustments on Access Bio convertible notes and the Glycosyn promissory note For the three months ended and the year ended December 31, 2020, primarily includes milestone payments under our agreement with the National Institutes of Health 38 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#39Stock-Based Compensation (Unaudited) In millions of USD Total Stock-Based Compensation Amount included in Research and Development expenses: Stock-Based Compensation Employer Payroll Taxes Related to Stock-Based Compensation Amount included in General and Administrative expenses Stock-Based Compensation Employer Payroll Taxes Related to Stock-Based Compensation Three Months Ended December 31, 2020 0.1 2021 1,672.8 930.3 926.7 3.6 742.5 741.1 1.4 0.0 0.0 0.0 0.1 0.1 0.0 % YoY NM NM NM NM NM NM NM 2021 1,687.6 930.4 926.7 3.6 757.2 755.8 1.4 Year Ended December 31, 2020 0.5 0.1 0.1 0.0 0.4 0.4 0.0 % YoY NM NM NM NM As previously disclosed, on November 17, 2021 the board of directors modified the vesting terms of RSUs, such that Ginkgo's business combination with Soaring Eagle Acquisition Corp. was deemed to have met the performance condition for vesting. This was accounted for as a modification and resulted in a catch-up adjustment of approximately $1.5 billion of incremental stock-based compensation expense in the fourth quarter of 2021 (calculated based on the number of RSUS impacted, which had been granted since 2015, at the share price of $13.59 on November 17, 2021). Stock-based compensation expense also increased by $173.5 million related to RSU earnout shares ("Earnout RSUs") which were also subject to the same performance condition as the underlying RSUS. NM NM NM Modification of Equity Awards in Connection with Business Combination In the fourth quarter, Ginkgo recognized $1.7 billion of stock-based compensation expense. Prior to becoming a public company in September 2021, Ginkgo granted restricted stock units ("RSUS") with both a service-based vesting condition and a performance-based vesting condition, defined as a change in control or an initial public offering (both as defined in the underlying award agreement). Ginkgo historically did not recognize any stock-based compensation expense associated with these awards due to the performance-based vesting condition. As of December 31, 2021, there was $2.2 billion of unrecognized stock-based compensation expense related to the above catch-up adjustment for those RSUS and Earnout RSUS that had not yet fully met the service-based vesting condition as of December 31, 2021. This amount will be recognized over a weighted-average period of 1.6 years. 39 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#40Foundry Revenue (Unaudited) In thousands of USD, except percentages Related Parties Third Parties Foundry Revenue Three Months Ended December 31, 2021 % of Total 30% 70% 100% 10,415 23,741 $34,156 2020 % of Total 12,751 78% 22% 3,668 $16,419 100% 2021 47,161 65,828 $112,989 Year Ended December 31, % of Total 42% 58% 100% 2020 42,535 16,686 $59,221 % of Total 72% 28% 100% Related Parties: Related parties include Platform Ventures (Joyn, Motif, Allonnia and Arcaea) and Structured Partnerships (Genomatica and Synlogic). See notes to our condensed consolidated financial statements for additional information related to transactions with related parties Third Parties: Includes all other customers 40 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW#41Update on M&A Activity We expect M&A to be an important strategic lever for Ginkgo, as we can acquire high potential technologies and deploy them at scale. Two deals recently announced: Project Beacon COVID-19 What: Project Beacon is a Boston-based social benefit organization focused on helping to increase the capacity, availability, accessibility, and affordability of COVID-19 testing. Why: Ability to bring on an experienced team and deepen relationship with Commonwealth of Massachusetts with minimal financial investment. When: Announced January 19, 2022 How: Strong, pre-existing relationship with Project Beacon made Concentric the acquirer of choice fgen What: FGen is a Swiss company specializing in ultra-high-throughput screening, using nanoliter reactor technology. Why: Enhances Ginkgo's cell screening and directed evolution capabilities. Technology can be broadly applied across many Ginkgo programs. When: Announced March 14, 2022 How: Multi-year partnership with FGen built trust and respect between the teams 41 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW